B
Bullisch
Bullisch · 25%CAMP
$1.48
Szenariopreis
$3.430
-0.215 (-6.28%)Zum Schluss
Loading chart…
- Hoch
- 3.800
- Eröffnung
- 3.660
- Volumengewichteter Durchschnittskurs
- 3.54
- Volumen
- 88.47K
- Marktkap.
- 660.34K
- Tief
- 3.380
- Umsatz
- 312.86K
- EV/EBITDA, TTM
- 8.64
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Bewertungskennzahlen
Das aktuelle erwartete KGV von CalAmp Corp (CAMP) beträgt 0.07, verglichen mit dem 5-Jahres-Durchschnitt von -23.57.
Alphio-AI-Kursszenarien für CAMP
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die CAMP halten
Event-Zeitleiste
News
9.009-10NewsfilterCAMP4 Receives MHRA Approval for Clinical Trials
9.508-17NASDAQ.COMCAMP4 Therapeutics Reports Q2 2026 Financial Results and Updates
9.508-04NASDAQ.COMBiotech Stocks Surge with Significant Gains
- 5.007-01Newsfilter
X4 Pharmaceuticals Appoints Kelly Gold to Board of Directors
6.006-16CNBCMajor Wall Street Rating Changes Overview
CAMP FAQ – beantwortet von Alphio AI
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders. It operates in the Technology sector (RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT industry).
Community
Mehr ↗
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.